Spiroplatin is a metal drug and analog of the second generation for cisplatin, developed for the treatment of cancer. Spiroplatin induces DNA cross-linking, thereby inhibiting DNA replication and the synthesis of RNA and protein. Initial clinical trials of spiroplatin have shown that it can cause less nausea and vomiting than cisplatin, and can be administered without hydration due to less renal toxicity. However, with increasing doses, the marginal toxicity was both renal and hematologic. In addition, spiroplatin was devoid of significant antitumor effects in advanced ovarian cancer, a disease in which some response can be expected. Based on these data, further development was discontinued.